Novartis announced the FDA approved updated labeling for inclisiran, a small-interfering RNA therapy, for use as monotherapy ...

These are study abroad programs that are administered by another SUNY campus. UB students who participate on another SUNY program abroad apply for the study abroad program through the sponsoring ...

Despite near universal availability of nirsevimab, only 35% of eligible children receive nirsevimab for RSV prophylaxis.